|
1
|
Mann KM, Ying H, Juan J, Jenkins NA and
Copeland NG: KRAS-related proteins in pancreatic cancer. Pharmacol
Ther. 168:29–42. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vijayvergia N and Cohen SJ: Personalized
medicine in sporadic pancreatic cancer without homologous
recombination-deficiency: Are we any closer? J Gastrointest Oncol.
7:727–737. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Miyoshi E and Kamada Y: Application of
glycoscience to the early detection of pancreatic cancer. Cancer
Sci. 107:1357–1362. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cheng S, Li Y, Yang Y, Feng D, Yang L, Ma
Q, Zheng S, Meng R, Wang S, Wang S, et al: Breast cancer-derived
K172N, D301V mutations abolish Na+/H+
exchanger regulatory factor 1 inhibition of platelet-derived growth
factor receptor signaling. FEBS Lett. 587:3289–3295. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shibata T, Chuma M, Kokubu A, Sakamoto M
and Hirohashi S: EBP50, a beta-catenin-associating protein,
enhances Wnt signaling and is over-expressed in hepatocellular
carcinoma. Hepatology. 38:178–186. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fraenzer JT, Pan H, Minimo L Jr, Smith GM,
Knauer D and Hung G: Overexpression of the NF2 gene inhibits
schwannoma cell proliferation through promoting PDGFR degradation.
Int J Oncol. 23:1493–1500. 2003.PubMed/NCBI
|
|
7
|
Yao W, Feng D, Bian W, Yang L, Li Y, Yang
Z, Xiong Y, Zheng J, Zhai R and He J: EBP50 inhibits EGF-induced
breast cancer cell proliferation by blocking EGFR phosphorylation.
Amino Acids. 43:2027–2035. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ma Q, Jiao Y, Hao Y, Yan S, Lyu N, Gao H,
Li D, Liu Q, Zheng J and Song N: Targeting of NHERF1 through RNA
interference inhibits the proliferation and migration of metastatic
prostate cancer cells. Oncol Lett. 11:1149–1154. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen X, Yang H, Zhang S, Wang Z, Ye F,
Liang C, Wang H and Fang Z: A novel splice variant of supervillin,
SV5, promotes carcinoma cell proliferation and cell migration.
Biochem Biophys Res Commun. 482:43–49. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Talbert EE, Yang J, Mace TA, Farren MR,
Farris AB, Young GS, Elnaggar O, Che Z, Timmers CD, Rajasekera P,
et al: Dual inhibition of MEK and PI3K/Akt rescues cancer cachexia
through both tumor extrinsic and intrinsic activities. Mol Cancer
Ther. 16:344–356. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
McCubrey JA, Rakus D, Gizak A, Steelman
LS, Abrams SL, Lertpiriyapong K, Fitzgerald TL, Yang LV, Montalto
G, Cervello M, et al: Effects of mutations in Wnt/beta-catenin,
hedgehog, Notch and PI3K pathways on GSK-3 activity-diverse effects
on cell growth, metabolism and cancer. Biochim Biophys Acta.
1863:2942–2976. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rumman M, Jung KH, Fang Z, Yan HH, Son MK,
Kim SJ, Kim J, Park JH, Lim JH and Hong S: HS-173, a novel PI3K
inhibitor suppresses EMT and metastasis in pancreatic cancer.
Oncotarget. 7:78029–78047. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li H, Zhang B, Liu Y and Yin C: EBP50
inhibits the migration and invasion of human breast cancer cells
via LIMK/cofilin and the PI3K/Akt/mTOR/MMP signaling pathway. Med
Oncol. 31:1622014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bellizzi A, Greco MR, Rubino R, Paradiso
A, Forciniti S, Zeeberg K, Cardone RA and Reshkin SJ: The
scaffolding protein NHERF1 sensitizes EGFR-dependent tumor growth,
motility and invadopodia function to gefitinib treatment in breast
cancer cells. Int J Oncol. 46:1214–1224. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
James MF, Beauchamp RL, Manchanda N,
Kazlauskas A and Ramesh V: A NHERF binding site links the betaPDGFR
to the cytoskeleton and regulates cell spreading and migration. J
Cell Sci. 117:2951–2961. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Curto M, Cole BK, Lallemand D, Liu CH and
McClatchey AI: Contact-dependent inhibition of EGFR signaling by
Nf2/Merlin. J Cell Biol. 177:893–903. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Meng R, Qin Q, Xiong Y, Wang Y, Zheng J,
Zhao Y, Tao T, Wang Q, Liu H, Wang S, et al: NHERF1, a novel GPER
associated protein, increases stability and activation of GPER in
ER-positive breast cancer. Oncotarget. 7:54983–54997. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Georgescu MM, Gagea M and Cote G:
NHERF1/EBP50 suppresses Wnt-beta-catenin pathway-driven intestinal
neoplasia. Neoplasia. 18:512–523. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lim HJ, Wang X, Crowe P, Goldstein D and
Yang JL: Targeting the PI3K/PTEN/AKT/mTOR pathway in treatment of
sarcoma cell lines. Anticancer Res. 36:5765–5771. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xiao J, Lin HY, Zhu YY, Zhu YP and Chen
LW: miR-126 regulates proliferation and invasion in the bladder
cancer BLS cell line by targeting the PIK3R2-mediated PI3K/Akt
signaling pathway. Onco Targets Ther. 9:5181–5193. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Peng Z, Wang Q, Zhang Y, He J and Zheng J:
EBP50 interacts with EGFR and regulates EGFR signaling to affect
the prognosis of cervical cancer patients. Int J Oncol.
49:1737–1745. 2016. View Article : Google Scholar : PubMed/NCBI
|
